These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12895200)

  • 61. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
    Iacob SA; Petrescu AM; Iacob DG
    Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
    Puoti M; Babudieri S; Rezza G; Viale P; Antonini MG; Maida I; Rossi S; Zanini B; Putzolu V; Fenu L; Baiguera C; Sassu S; Carosi G; Mura MS
    Antivir Ther; 2004 Aug; 9(4):627-30. PubMed ID: 15456094
    [TBL] [Abstract][Full Text] [Related]  

  • 63. New interferon approved for chronic hepatitis C.
    Am J Health Syst Pharm; 1997 Dec; 54(23):2656. PubMed ID: 9408506
    [No Abstract]   [Full Text] [Related]  

  • 64. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Yurci A; Guven K; Torun E; Gursoy S; Baskol M; Akgun H; Ozbakir O; Yucesoy M
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):811-5. PubMed ID: 17700270
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Elevated hepatic transaminases associated with the use of interferon alfacon-1 and ribavirin.
    Kleppinger EL; Ragan AP
    Am J Health Syst Pharm; 2009 Mar; 66(5):465-8. PubMed ID: 19233994
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I; Rigla M; Torras X; Enríquez J; Corcoy R
    Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
    [No Abstract]   [Full Text] [Related]  

  • 68. [Convulsive seizure during a treatment with interferon alpha for chronic viral hepatitis C].
    Verger P; De Monredon J; Blais J
    Gastroenterol Clin Biol; 1997; 21(11):902-3. PubMed ID: 9587549
    [No Abstract]   [Full Text] [Related]  

  • 69. Peginterferon and ribavirin for hepatitis C.
    Evoli A; Servidei S
    N Engl J Med; 2007 Mar; 356(12):1269-70; author reply 1271. PubMed ID: 17380575
    [No Abstract]   [Full Text] [Related]  

  • 70. Acute reversible rhabdomyolysis during interferon alpha2B therapy for hepatitis C.
    Gabrielli M; Santarelli L; Serricchio M; Leo D; Pola P; Gasbarrini A
    Am J Gastroenterol; 2003 Apr; 98(4):940. PubMed ID: 12738487
    [No Abstract]   [Full Text] [Related]  

  • 71. [Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases].
    Jia YH; Gao SJ; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):67-8. PubMed ID: 22489302
    [No Abstract]   [Full Text] [Related]  

  • 72. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
    Gergely AE; Lafarge P; Fouchard-Hubert I; Lunel-Fabiani F
    Hepatology; 2002 May; 35(5):1281-2. PubMed ID: 11981781
    [No Abstract]   [Full Text] [Related]  

  • 73. Bilateral non-arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C.
    Chan JW
    Eye (Lond); 2007 Jun; 21(6):877-8. PubMed ID: 17318204
    [No Abstract]   [Full Text] [Related]  

  • 74. [Thyroid dysfunction in patients with chronic hepatitis C treated with pegylated interferon alpha].
    Montero-Tinnirello J; de la Fuente-Aguado J; Rodríguez-Pecci MS; Fernández-Fernández FJ
    Rev Clin Esp; 2011 Sep; 211(8):436-8. PubMed ID: 21546017
    [No Abstract]   [Full Text] [Related]  

  • 75. Interferon alpha-induced lupus: proof of principle.
    Niewold TB
    J Clin Rheumatol; 2008 Jun; 14(3):131-2. PubMed ID: 18525429
    [No Abstract]   [Full Text] [Related]  

  • 76. [Pathological consequences of excess of interferon in vivo].
    Lebon P; Crow YJ; Casanova JL; Gresser I
    Med Sci (Paris); 2019 Mar; 35(3):232-235. PubMed ID: 30931907
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rheumatoid arthritis-like disease after alpha-interferon therapy.
    Chazerain P; Meyer O; Kahn MF
    Ann Intern Med; 1992 Mar; 116(5):427. PubMed ID: 1736783
    [No Abstract]   [Full Text] [Related]  

  • 78. Thrombosis and recombinant interferon-alpha.
    Durand JM; Quiles N; Kaplanski G; Soubeyrand J
    Am J Med; 1993 Jul; 95(1):115-6. PubMed ID: 8328488
    [No Abstract]   [Full Text] [Related]  

  • 79. Severe neuropathy associated with low-dose recombinant interferon-alpha.
    Gastineau DA; Habermann TM; Hermann RC
    Am J Med; 1989 Jul; 87(1):116. PubMed ID: 2741970
    [No Abstract]   [Full Text] [Related]  

  • 80. Digital vasculitis associated with interferon therapy.
    Reid TJ; Lombardo FA; Redmond J; Hammond SL; Coffey JA; Ozer H
    Am J Med; 1992 Jun; 92(6):702-3. PubMed ID: 1605155
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.